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Abstract: CYP2D6 differences have already been demonstrated within Latin American populations by the 
CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics (RIBEF, as per the acronym in 
Spanish). However, within the population of Costa Rica, no research has been conducted until now, even though 
this population has a trihybrid component ancestry that represents an interesting condition. Thus, the present 
study was aimed to determine the frequency of Ultra-rapid Metabolizers (UMs) and Poor Metabolizers (PMs) 
in a Costa Rican population, as well as to determine whether there are differences in the CYP2D6-predicted 
phenotype frequencies among three Costa Rican groups with different ethnic backgrounds. Additionally, these 
frequencies of PMs and UMs obtained were compared with Ibero-American populations published data. Finally, 
we also aimed to describe allele frequencies among different Costa Rican ethnic groups. This research has been 
undertaken within the framework of the RIBEF CEIBA Consortium studies on Latin American populations. A 
total of 385 individuals were included in the study: 139 mestizos, 197 Amerindians, and 49 Afro-Caribbeans. 
CYP2D6 genotypes were determined by XL-PCR and Real-Time PCR. The CYP2D6 variant alleles *2, *3, *4, 
*5, *6, *10, *17, *29, *35 and *41 were also determined. For the entire Costa Rican population, the frequency 
of PMs and UMs was 6% and 6.5%, respectively. The percentage of UMs in the mestizo population was higher 
than in the Amerindian population. CYP2D6 UMs vary from 3.6% to 10.1% and PMs from 1.4% to 10.2% 
among three Costa Rican groups. The highest frequencies of UMs (10.1%) and PMs (10.2%) were found in the 
mestizo and Amerindian populations, respectively. In conclusion, the frequencies of UMs and PMs for CYP2D6 
varied widely across the mestizo, Amerindian and Afro-Caribbean Costa Rican populations. Future research in 
this population should be oriented to identify new CYP2D6 variants through sequencing methods, as well as to 
determine CYP2D6 phenotype, in order to establish the phenotype-genotype relation. Finally, further studies 
involving genetic markers of ancestry are needed in the Costa Rican population. Rev. Biol. Trop. 62 (4): 1659-
1671. Epub 2014 December 01.
Key words: CYP2D6, Costa Rica, Amerindian, Afro-Caribbean, mestizo, populations, Poor Metabolizers, Ultra-
rapid Metabolizers.
CYP2D6 is involved in the metabolism 
of widely used drugs, such as antidepressants, 
antipsychotics, antihypertensives, analgesics, 
and beta-blockers (Ingelman-Sundberg, 2005). 
The CYP2D6 gene, located on chromosome 
22q13.1, is highly polymorphic, with alleles 
causing absent, reduced, normal and increased 
catalytic activity (CYP Alleles Nomenclature 
Database). 
Inter-ethnic differences in such cyto-
chrome P450 polymorphism might be partially 
responsible for the variations in drug disposi-
tion among populations. During the 16th cen-
tury, people from the Iberian Peninsula arrived 
to different places of America leading cur-
rent Costa Rican, Latin American, and Carib-
bean populations to have different degrees of 
admixture (Gaedigk et al., 2010; Llerena et 
1660 Rev. Biol. Trop. (Int. J. Trop. Biol. ISSN-0034-7744) Vol. 62 (4): 1659-1671, December 2014
al., 2012; Montané-Jaime, Lalla, Steimer, & 
Gaedigk, 2013). Latin American populations 
are products of a process of admixture, mainly 
including groups of Amerindian, European 
and African ancestry (Sans, 2000). The Costa 
Rican population has been described as hav-
ing estimated mean ancestry proportions for 
European, Amerindian, and African compo-
nents of 54%, 32%, and 13%, respectively 
(Segura-Wang, Raventós, Escamilla, & Barran-
tes, 2010). Therefore, it could be of relevance 
to determine potential differences across the 
multi-ethnic Costa Rican population.
A high frequency of Ultra-rapid Metabo-
lizers (UMs) has been previously described 
in Spanish population (Llerena, Dorado, & 
Peñas-Lledó, 2009; Peñas-Lledó et al., 2012). 
Given the Iberian Peninsula’s influence on 
the hybrid population, we hypothesized that a 
high frequency of UMs would be present in the 
mestizo population. It was also hypothesized 
that high frequencies of CYP2D6*17 would be 
found in the Afro-Caribbean population due to 
their African ancestry and CYP2D6*10 within 
the Amerindian population due to their Asian 
ancestry (Bradford, 2002).
In Central American countries, there are 
just a few studies in Panama (Arias et al., 1986; 
Arias, Jorge, Lee, Barrantes, & Inaba, 1988), 
Nicaragua (Llerena et al., 2012; Llerena et al., 
2013) and Costa Rica (reporting some alleles of 
a Costa Rican Amerindian population) (Jorge 
& Arias, 1995). CYP2D6 genetic polymor-
phisms studies have been carried out in Latin 
American countries supported by the CEIBA.
FP Consortium of the Ibero-American Network 
of Pharmacogenetics & Pharmacogenomics 
(RIBEF) (de Andrés et al., 2013; Rodeiro et al., 
2012), including Ecuadorians (Dorado et al., 
2012), Mexicans (Sosa-Macías, Dorado, Ala-
nis-Bañuelos, Llerena, & Lares-Asseff, 2010) 
and Cubans (González et al., 2008; Llerena et 
al., 2012; Llerena et al., 2013; Peñas-Lledó, 
Dorado, Pacheco, González, & Llerena, 2009). 
However, this will constitute the first report 
of a Costa Rican population including groups 
from different ethnic backgrounds.
The present study aimed to determine 
the frequency of UMs and Poor Metabolizers 
(PMs) in a Costa Rican population, as well 
as to determine whether there are differences 
in CYP2D6-predicted phenotype frequencies 
among three Costa Rican groups with dif-
ferent ethnic backgrounds. Additionally, the 
frequency of PMs and UMs obtained in this 
study was compared with published data from 
Ibero-American populations, and finally, this 
study also aimed to describe allele frequencies 
among different Costa Rican ethnic groups.
MATERIALS AND METHODS
Subjects: The study comprised 385 
healthy individuals belonging to three ethnic 
groups: Amerindian (n=197), Afro-Caribbean 
(n=49) and mestizo (n=139). 
The DNA samples were obtained from 
a DNA biobank of the School of Biology of 
the University of Costa Rica. The samples 
were collected and stored after approval from 
review boards of the University of Costa Rica, 
and have been widely studied (Azofeifa et 
al., 2004; Barrantes et al., 1990; Barrantes, 
Smouse, Neel, Mohrenweiser, & Gershowitz, 
1982; Barrantes, 1993a, 1993b; Morera, Bar-
rantes, & Marin-Rojas, 2003; Morera & Bar-
rantes, 2004; Reich et al., 2012; Santos, Ward, 
& Barrantes, 1994; Thompson, Neel, Smouse, 
& Barrantes, 1992; Wang et al., 2007, 2008). 
All the samples were already classified accord-
ing to the ethnic origin and previous studies 
(see inclusion criteria), codified, and stored 
with an ID. Demographic data of these popula-
tions are available elsewhere (Barrantes, 1989; 
Madrigal, 2006; Morera et al., 2003).
The inclusion criteria were:
•	 Phenotype features: For the Amerindian 
population, the criteria were copper-colo-
red skin, straight hair, slanted eyes, and 
short stature; in the Afro-Caribbean popu-
lation, dark skin, curly hair, flat nose, and 
prominent cheekbones were the criteria; 
the Mestizo population comprised all those 
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subjects not included in any of the afore-
mentioned groups.
•	 Places of residence: For the Amerin-
dian group, the places of residence were 
Matambu Indian locality (Chorotega), the 
South and the Pacific area (Guaymi), the 
Atlantic Talamanca and the Pacific area 
(Cabecar), the Talamanca area (Bribri), 
the Quitirrisi and Zapaton Indian locali-
ties (Huetar), and the Margarita and Ton-
jibe Guatuso Indian localities (Guatuso 
or Maleku). The samples of the Afro-
Caribbean population were collected from 
volunteers living in the Atlantic coastal 
region of Limon. The mestizo population 
was selected from people living in the 
Guanacaste region, and in the Western or 
Central Valley of Costa Rica (Fig. 1). The 
inclusion of an individual in a group exclu-
ded that individual from being part of any 
other population.
•	 Genetic markers such as blood group 
systems: ABO (O for Amerindians and B 
for the Afro-Caribbeans), rhesus, MNS, 
P, Kell, Kidd, Duffy, Diego, and Lewis; 
plasmatic protein systems (albumin, trans-
ferrin, haptoglobin, and ceruloplasmin) 
(Barrantes et al., 1990; Bieber, Bieber, 
Rodewald, & Barrantes, 1996); single 
nucleotide polymorphisms (SNPs) (Herr-
mann et al., 2002); microsatellites (Wang 
et al., 2007); mitochondrial DNA (Santos 
et al., 1994) and chromosome Y (Ruiz-
Narváez et al., 2005).
Genotyping procedure: For genotyping, 
the CEIBA.FP Consortium methodology was 
followed. To detect the presence of allelic 
variants harboring a CYP2D6*5 gene dele-
tion or a duplication, long range (XL)-PCR 
was performed as described in detail else-
where (Fig. 2) (Dorado et al., 2005). Subjects 
Fig. 1. The approximate geographic locations of the Costa Rican populations studied. 1: mestizo population. 2: Bribri. 3: 
Guaymi. 4: Cabecar. 5: Guatuso. 6: Chorotega. 7: Huetar. 8: Afro-Caribbean population.
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positive for a duplication or deletion were 
further characterized for gene copy number 
with the TaqMan assay Hs00010001_cn, which 
specifically amplifies exon 9 sequences and 
does not amplify CYP2D7 or CYP2D8 pseu-
dogenes or CYP2D6/CYP2D7 hybrids alleles 
carrying CYP2D7 exon 9 sequences. Genotype 
analysis for the CYP2D6*2 (-1584 C>G), *3 
(2549A>del), *4 (100 C>T, 1846G>A), *6 
(1707 T>del), *10 (100 C>T), *17 (1023 
C>T), *29 (3183 G>A), *35 (-1584 C>G and 
31 G>A), and *41 (2988 G>A) allelic vari-
ants was carried out on genomic DNA, using 
commercially available TaqMan assays as pre-
viously described (Dorado et al., 2012). To dis-
criminate among CYP2D6*1xN, *2xN, *4xN 
and *10xN alleles, a 10kb long XL-PCR frag-
ment was generated from duplication-positive 
subjects and tested for respective SNPs by an 
established PCR-RFLP approach (Dorado et 
al., 2005).
Predicted hydroxylation capacity group: 
In order to extrapolate genetic data to metabol-
ic phenotype information, an activity score was 
utilized as previously described (Gaedigk et al., 
2008; Llerena et al., 2012). 
Zero value was assigned to CYP2D6*3, 
*4, *4XN, *5, *6 variants; 0.5 to each copy of 
CYP2D6*10, *17, *29, *41 alleles; one was 
assigned to CYP2D6 wt, *2, *35, and more 
than two (depending on the number of copies) 
to the multiplication of the active alleles (wtxN, 
*2xN). Individuals with zero active genes were 
classified as poor metabolizers (PMs), and 
those with more than two active gene copies 
were classified as Ultra-rapid Metabolizers 
(UMs) (Gaedigk et al., 2008; Llerena et al., 
2012).
The differences in CYP2D6 allele frequen-
cies were compared using the X2-test and/or 
Fisher’s exact test. P-values <0.05 were regard-
ed as statistically significant. Hardy-Weinberg 
equilibrium was determined by comparing the 
genotype frequencies with the expected values 
using a contingency table X2 statistic with 
Yate’s correction. Statistical analyses were 
performed using the STATISTICA 4.3 (Stat-
Soft, Tulsa, OK, USA) and GraphPad Prism 
3.02 (GraphPad Software, San Diego, CA, 
USA) software.
RESULTS
CYP2D6 allele frequencies are given in 
table 1. Multiplications of active genes (wtxN, 
*2xN) were present in 15 individuals of the 
mestizo population and in seven of each of the 
Amerindian and Afro-Caribbean populations 
(Table 1). 
Null activity alleles *4 and *5 frequen-
cies in the Amerindian population were higher 
(22.6% and 4.8%, respectively) than in the 
mestizo group (10.4% and 3.2%, respectively; 
p<0.05) (Table 1). The frequencies of alleles 
with decreased activity (*17 and *29) in the 
Afro-Caribbean population were higher (18.4% 
and 11.2%) than in the other two populations 
(p<0.05), and the CYP2D6*10 frequency in the 
Fig. 2. PCR output for CYP2D6*5 on a 0.8% agarose gel. Identification of lanes (from left to right) 1: positive control 
(5.1kb + 3.5kb), 2 and 4-7: samples negative for deletion (wild-type; 5.1kb) and 3: sample positive for deletion (CYP2D6*5).
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Amerindian population (0.3%) was lower than 
in the Afro-Caribbean (3.1%; p<0.05).
The CYP2D6 frequencies for each activ-
ity score group are given in table 1. The entire 
Costa Rican population frequency of PMs and 
UMs were 6% and 6.5% respectively.
As expected, the percentage of UMs in the 
mestizo population (10.1%) was higher than 
in the Amerindian population (3.6%, p<0.05) 
(Table 1). However, the frequency of individu-
als classified as PMs (zero active genes) was 
higher in Amerindians (10.2%) than in the 
mestizo population (1.4%, p<0.05). The fre-
quency of UMs (8.2%) and PMs (2%) of the 
Afro-Caribbean population was not different 
to any of the Costa Rican populations studied.
The frequencies of CYP2D6 genotypes 
are listed in table 2. The mestizo population 
showed more diversity concerning genotypes 
in comparison with the other Costa Rican pop-
ulations studied. In all three groups, the most 
frequently found CYP2D6 genotypes belonged 
to the classification of two active genes (Table 
2). Published data from Latin American popu-
lations is used to compare results with the 
Costa Rican populations (Table 3).
DISCUSSION
To the best of our knowledge, this is the 
first study in a Costa Rican population that 
TABLE 1
CYP2D6 allele and active gene frequencies in three Costa Rican ethnic groups studied
Allele
Costa Rica Mestizo Amerindian Afrocaribbean
n=385 Frequency n=278 Frequency n=394 Frequency n=98 Frequency
wt 370 0.481 134 0.482 199 0.505 37 0.378 * **
*2 115 0.149 50 0.180 59 0.150 6 0.061 * **
*3 5 0.006 4 0.014 0 0.000 1 0.010
*4 122 0.158 29 0.104 89 0.226 * 4 0.041 **
*5 32 0.042 9 0.032 19 0.048 * 4 0.041
*6 2 0.003 2 0.007 0 0.000 * 0 0.000
*10 7 0.009 3 0.011 1 0.003 3 0.031 **
*17 31 0.040 6 0.022 7 0.018 18 0.184 * **
*29 17 0.022 4 0.014 2 0.005 11 0.112 * **
*35 5 0.006 1 0.004 3 0.008 1 0.010
*41 26 0.034 17 0.061 8 0.020 * 1 0.010
wtxN 16 0.021 8 0.029 4 0.010 4 0.041
*2xN 13 0.017 7 0.025 3 0.008 3 0.031
*4xN 6 0.008 4 0.014 0 0.000 * 2 0.020 **
*10xN 2 0.003 0 0.000 0 0.000 2 0.020 **
*17xN 1 0.001 0 0.000 0 0.000  1 0.010   
Active genesa
0 0.060 2 0.014 20 0.102 * 1 0.020
0.5 0.052 10 0.072 6 0.030 4 0.082
1 0.270 32 0.230 62 0.315 8 0.163
1.5 0.114 18 0.129 12 0.061 16 0.327
2 0.439 63 0.453 90 0.457 16 0.327
>2 0.065 14 0.101 7 0.036 * 4 0.082
n: number of subjects. *p<0.05 compared with mestizo by Fisher’s exact Test. **p<0.05 compared with the Amerindian 
group by Fisher’s exact Test. aCYP2D6*3, *4, *4XN, *5, *6 variants were assigned the value of zero; CYP2D6*10, *17, *29, 
*41 alleles were assigned 0.5 for each copy; CYP2D6 wt, *2, *35 were assigned one, and the multiplication of the active 
alleles (wtxN, *2xN) were assigned ≥2 (depending on the number of copies).
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TABLE 2




n Frequency Expected freq n Frequency Expected freq n Frequency Expected freq
*4/*4 0 1 0.007 0.011 13 0.066 0.051 0 _ 0.002
*4/*5 0 1 0.007 0.007 7 0.036 0.022 0 _  
*3/*4x3 0 0 _  0 0.000  1 0.020  
*3/*41 0.5 1 0.007 0.002 0 _  0 _  
*4/*10 0.5 0 _  1 0.005 0.001 0 _  
*4/*17 0.5 2 0.014 0.005 4 0.020 0.008 0 _  
*4/*29 0.5 0 _  0 _  1 0.020 0.009
*4/*41 0.5 3 0.022 0.013 1 0.005 0.009 0 _  
*5/*17 0.5 0 _  0 _  2 0.041 0.015
*5/*29 0.5 0 _  0 _  1 0.020 0.009
*5/*41 0.5 1 0.007 0.004 0 _  0 _  
*6/*41 0.5 1 0.007 0.001 0 _  0 _  
*4x2/*10 0.5 2 0.014 0.000 0 _  0 _  
wt/*3 1 1 0.007 0.013 0 _  0 _  
wt/*4 1 16 0.115 0.100 33 0.168 0.228 0 _  
wt/*5 1 4 0.029 0.031 10 0.051 0.048 1 0.020 0.031
*2/*4 1 5 0.036 0.037 16 0.081 0.068 0 _  
*2/*5 1 3 0.022 0.012 2 0.010 0.014 0 _  
*2/*6 1 1 0.007 0.003 0 _  0 _  
*4/*35 1 0 _  1 0.005 0.004 0 _  
*10/*17 1 0 _  0 _  2 0.041 0.011
*17/*17 1 0 _ 0 _ 2 0.041 0.034
*17/*29 1 0 _  0 _  2 0.041 0.041
wt/*4xN# 1 2 0.014 0.013 0 _  0 _  
*2/*4X3 1 0 _  0 _  1 0.020  
wt/*10 1.5 0 _  0 _  1 0.020 0.023
wt/*17 1.5 4 0.029 0.021 1 0.005 0.018 4 0.082 0.139
wt/*29 1.5 3 0.022 0.013 0 _ 0.005 6 0.122 0.085
wt/*41 1.5 6 0.043 0.059 6 0.030 0.020 1 0.020 0.008
*2/*17 1.5 0 _ 2 0.010 0.005 1 0.020 0.022
*2/*29 1.5 0 _  2 0.010 0.002 0 _  
*2/*41 1.5 4 0.029 0.022 1 0.005 0.006 0 _  
*10/*35 1.5 1 0.007 0.000 0 _  0 _  
*17/*35 1.5 0 _  0 _  1 0.020 0.004
*10x2/*17 1.5 0 _  0 _  1 0.020  
*17x2/*29 1.5 0 _  0 _  1 0.020  
wt/wt 2 28 0.201 0.232 60 0.305 0.255 9 0.184 0.143
wt/*2 2 32 0.230 0.174 21 0.107 0.152 2 0.041 0.046
wt/*35 2 0 _ 0.004 1 0.005 0.008 0 _ 0.008
*2/*2 2 2 0.014 0.032 7 0.036 0.023 1 0.020 0.004
*2/*35 2 0 _  1 0.005 0.002 0 _  
wtx2/*3 2 1 0.007 0.001 0 _  0 _  
wtx2/*4 2 0 _  0 _  3 0.061  
wt/*10x2 2 0 _  0 _  1 0.020  
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examined the predicted metabolic phenotype 
frequencies of CYP2D6 (UMs and PMs) in 
three ethnic groups. The entire Costa Rican 
population frequency of PMs (6%) is consistent 
with the Portuguese (Albuquerque et al., 2013), 
the Mexican-American (Casner, 2005), and the 
Colombian mestizo (Isaza, Henao, López, & 
Cacabelos, 2000) populations. Likewise, the 
frequency of UMs for the Costa Rican popula-
tion is similar to those reported for the Spanish 
population (6.1%) (Peñas-Lledó et al., 2012).
Considering the ethnicity of the analyzed 
populations, the frequency of UMs in the mes-
tizo group (10.1%) is similar to those reported 
in a Spanish population (6.1%) (Peñas-Lledó et 
al., 2012), those of a Mexican admixed popula-
tion (9.1%) (López, Guerrero, Jung-Cook, & 
Alonso, 2005), and it is lightly greater than the 
percentage of UMs determined with debriso-
quine in a Spanish population (5.2%, p=0.053) 
(Llerena et al., 2009). Moreover, the high fre-
quency of PMs in the Costa Rican Amerindian 
population (10.2%) is similar to that reported 
in an Amerindian population from Argentina 
and Paraguay (12.8%) (Bailliet et al., 2007). 
Despite the small number of individuals in the 
Afro-Caribbean group, the frequencies of PMs 
and UMs are comparable to those of Brazil-
ian populations with African ancestry (Kohl-
rausch et al., 2009; Silveira, Canalle, Scrideli, 
Queiroz, & Tone, 2009).
Individuals carrying two inactive alleles 
will produce a non-functional protein. There-
fore, all of them will likewise be determined 
as PMs in phenotyping studies. However, dis-
cordance between the identification of UMs 
by molecular methods and phenotype has been 
reported (Llerena et al., 2012; Løvlie, Daly, 
Molven, Idle, & Steen, 1996), so the predicted 
phenotype estimation needs to be confirmed 
with phenotyping studies.
Variability of CYP2D6 alleles was found 
within this Costa Rican population, in accor-
dance with the finding that the Costa Rican 
population is genetically heterogeneous (More-
ra et al., 2003; Morera & Barrantes, 2004). The 
high frequency of PMs in the Amerindian group 
can mainly be accounted for by the presence of 
the null allele CYP2D6*4 in this population 
(22.6%) at a frequency similar to those found 
in Amerindian populations of Argentina-Para-
guay (17.8%) (Bailliet et al., 2007). However, 
it is higher than those reported in Panamanian 
Embera (14%) and Ngwabe (17.1%) popula-
tions (p<0.05) (Jorge, Eichelbaum, Griese, 
Inaba, & Arias, 1999).
Regarding reduced activity alleles, the 
CYP2D6*17 and CYP2D6*29 frequencies in 
the Afro-Caribbean population were similar to 
those reported for an Afro-American popula-
tion (Gaedigk, Bradford, Marcucci, & Leeder, 





n Frequency Expected freq n Frequency Expected freq n Frequency Expected freq
wt/wtxN+ >2 5 0.036 0.028 4 0.020 0.010 1 0.020  
wt/*2xN^ >2 5 0.036 0.024 3 0.015 0.008 2 0.041  
wtx5/*3 >2 1 0.007 0.001 0 _  0 _  
wtx3/*41 >2 1 0.007 0.004 0 _  0 _  
*2x2/*2 >2 1 0.007 0.009 0 _  0 _  
*2x3/*17 >2 0 _  0 _  1 0.020  
*2x2/*29 >2 1 0.007 0.001 0 _  0 _  
n: number of subjects. #N=2 in one individual, N=3 in one individual. +N=2 in three individuals from the mestizo group, 
three from the Amerindian group, and in one individual from the Afro-Caribbean group; N=3 in two individuals from 
the mestizo group and one from the Amerindian group. ^N=2 in three individuals from the mestizo group, three from the 
Amerindian group and in two individuals from the Afro-Caribbean group; N=3 in one individual from the mestizo group; 
N=4 in one individual from the mestizo group.
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TABLE 3
Percentages (%) of UMs and PMs for CYP2D6 predicted phenotypes and phenotypes in the Costa Rican population 













Argentina-Paraguay Amerindian 86 12.8 (Bailliet et al., 2007)
Brazil African 33 0 (Silveira et al., 2009)
Mulatto 89 1.1 (Silveira et al., 2009)
Caucasian 178 2.8 (Silveira et al., 2009)
Brazil African 87 3.5 3.5 (Kohlrausch et al., 2009)
Caucasian 92 3.3 9.8 (Kohlrausch et al., 2009)
Cuba Caucasian 130 2.3 6.2 (Llerena et al., 2012)
Admixed 126 2.4 4.8 (Llerena et al., 2012) 
Ecuador Admixed 118 0.8 1.7 (Llerena et al., 2012) 
Mexico Mexican-American 50 6 6 (Casner, 2005)
Mexico Mexican-American 264 2.7 1.1 (Luo, Gaedigk, Aloumanis, & Wan, 2005)
Mexico Admixed 349 1.7 (Mendoza et al., 2001)
Mexico Admixed 285 3.2 (Mendoza et al., 2001) 
Mexico Admixed 243 2.1 9.1 (López et al., 2005)
Mexico Admixed 100 10 (López et al., 2005)
Mexico Amerindian 58 0 (Sosa-Macías et al., 2006)
Admixed 88 6.8 (Sosa-Macías et al., 2006)
Amerindian 85 0 (Sosa-Macías et al., 2006)
Admixed 110 3.6 (Sosa-Macías et al., 2006)
Nicaragua Admixed 98 4.1 3.1 (Llerena et al., 2012)
Panama-Colombia Amerindian/Ngawbe 344 4.4 (Jorge et al., 1999)
Amerindian/Embera 153 2.2 (Jorge et al., 1999)
Panama Amerindian-Cuna 51 0 (Arias et al., 1986)
Panama Amerindian-Ngawbe Guaymi 121 5.2 (Arias et al., 1988)
Portugal Caucasian 300 6.3 4.3 (Albuquerque et al., 2013)
Spain Caucasian 925 4.9 (Llerena , 1993)
Spain Caucasian 327 7 6.1 (Peñas-Lledó et al., 2012)
Spain Caucasian 290 2.4 (Crescenti et al., 2007)
Uruguay Admixed 302 7.3 (Estevez, Giusti, Parrillo, & Oxandabarat, 1997)
Venezuela Admixed 100 3 (Griman, Moran, Camargo, & Chiurillo, 2009)
Venezuela Admixed 149 2.01 (Griman et al., 2012)
Amerindian/Bari 40 25 (Griman et al., 2012)
Amerindian/Panare 46 0 (Griman et al., 2012)
Amerindian/Pemon 40 0 (Griman et al., 2012)
Amerindian/Warao 29 0 (Griman et al., 2012)
 Amerindian/Wayuu 24 0    (Griman et al., 2012)
Costa Rica Admixed 139 1.4 10.1 This study
Amerindian 197 10.2 3.6
 Afro-Caribbean 49 2 8.2   
n= number of subjects; Ref.=references.
1667Rev. Biol. Trop. (Int. J. Trop. Biol. ISSN-0034-7744) Vol. 62 (4): 1659-1671, December 2014
(Bradford, 2002). Moreover, the CYP2D6*10 
frequency in the Amerindian group (0.3%) was 
similar to that of the Tepehuano (0%) (Sosa-
Macías et al., 2006, 2010) and Mapuche (1.8%) 
(Muñoz et al., 1998) populations, but lower 
than other Amerindian populations (7.1% and 
6.9%; p<0.05) (Bailliet et al., 2007; Jorge et 
al., 1999). 
A limitation of this study was that the num-
ber of individuals in the Afro-Caribbean popu-
lation was low (n=49). Moreover, the inclusion 
criteria did not include ancestry informative 
markers analysis (AIMs). In this sense, further 
studies involving genetic markers of ancestry 
are needed in the Costa Rican population. It is 
necessary to remark that even though this study 
reports allele frequencies of CYP2D6 for Costa 
Ricans, they might not be representative of the 
population and might have been influenced by 
random effects.
Furthermore, the study of populations with 
complex ancestry such as Latin American pop-
ulations comprises the fact that novel or rare 
variants (Fohner et al., 2013; Gaedigk et al., 
2010) might appear, leading to poor metabo-
lism or reduced function (Montané-Jaime et al., 
2013). In the future, sequencing the CYP2D6 
gene in these populations might be suitable to 
detect relevant genetic variants.
Given the percentage of UMs found in the 
mestizo and Afro-Caribbean population and 
of PMs in the Amerindian group, it might be 
appropriate to follow available guidelines that 
provide information relating to the interpreta-
tion of CYP2D6 genotype test results to guide 
the dosing of different drugs (Crews et al., 
2012; Hicks et al., 2013). Likewise, the infor-
mation provided by this study supports that it 
might be appropriate to consider the develop-
ment of drug treatment guidelines taking into 
account population ethnic background, mean-
ing specific alleles of the population tested, 
to improve drug safety and efficacy in Costa 
Rican and Latin American populations. 
In conclusion, we report here for the first 
time the frequency of PMs (6%) and UMs 
(6.5%) in a Costa Rican population. Secondly, 
we found a difference between the frequency 
of predicted UM and PM phenotype across 
ethnicity in Costa Ricans.
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RESUMEN
Antecedentes étnicos y polimorfismo genético del 
CYP2D6 en los costarricenses. El Consorcio de la Red 
Iberoamericana de Farmacogenética CEIBA.FP ha demos-
trado que existen diferencias en cuanto a CYP2D6 en las 
poblaciones latinoamericanas. Sin embargo, hasta ahora, se 
sabe poco de este gen de importancia farmacogenética en la 
población de Costa Rica, la cual tiene una ancestría trihí-
brida. El presente estudio tiene como objetivos: determinar 
la frecuencia de los fenotipos extrapolados de CYP2D6 
en una población costarricense y determinar si existen 
diferencias en cuanto a las frecuencias de metabolizadores 
lentos (PMs) y ultra-rápidos (UMs) entre tres grupos con 
distinto origen étnico. Adicionalmente, las frecuencias de 
PMs y UMs obtenidas en este estudio fueron comparadas 
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con datos de poblaciones iberoamericanas. Por último, se 
pretende describir las frecuencias alélicas en los distintos 
grupos. En el estudio se incluyeron 385 muestras de indi-
viduos: 139 mestizos, 197 amerindios y 49 afro-caribeños. 
Los genotipos CYP2D6 fueron determinados por XL-PCR 
y PCR tiempo real. Se determinaron las variantes alélicas 
*2, *3, *4, *5, *6, *10, *17, *29, *35 y *41. Para la pobla-
ción total estudiada las frecuencia de PMs y UMs fueron 
respectivamente 6% y 6.5%. El porcentaje de individuos 
UMs fue mayor en la población mestiza que en la ame-
rindia. La frecuencia de UMs varió de 3.6 a 10.1% y la 
de PMs de 1.4 a 10.1% en los grupos costarricenses. Las 
frecuencias más altas de UMs (10.1%) y de PMs (10.2%) 
se encontraron respectivamente en las poblaciones mestiza 
y amerindia. En conclusión, las frecuencias de UMs y 
PMs de CYP2D6 varían ampliamente en las poblaciones 
mestiza, amerindia y afro-caribeña de Costa Rica. Inves-
tigaciones futuras en la población de Costa Rica deberían 
orientarse a identificar nuevas variantes del CYP2D6 
mediante métodos de secuenciación, así como a determi-
nar el fenotipo de CYP2D6 con el objetivo de establecer 
la relación fenotipo-genotipo. Finalmente, es necesario 
realizar estudios adicionales que involucren marcadores 
genéticos de ancestría en la población costarricense.
Palabras clave: CYP2D6, Costa Rica, amerindios, afro-
caribeños, mestizos, poblaciones, metabolizadores lentos, 
metabolizadores ultra-rápidos.
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